2 sites + 2 growing systems = less risk

Puro’s indoor plants at Waihopai are a mixture of CBD and THC varieties, with high, moderate and low levels of THC. Our research facility here will host Puro’s Cultivar Breeding Programme, being overseen by AbacusBio, and in future will provide ‘pharmaceutical grade’ flower products year-round.

At Kēkerengū the outdoor crop is a mixture of CBD and CBG dominant plants with low to no THC, which are being grown under organic protocols. Here Puro will manually harvest and boutique-process portions of its outdoor top flower, so it can provide options for a premium product for local and export markets. The remainder of Puro’s outdoor plants will be machine-processed and sold in bulk form suitable for high value extraction.  Our first commercial harvest at Kēkerenū is now underway.

Cultivating two very different plant varieties across two distinct sites gives Puro access to two unique markets, and two distinct income streams. This diversification of sites, products and markets reduces Puro’s risk profiles. We expect this will translate into reliable returns to our shareholders.

Our goal at both sites is to produce broad-spectrum products which provide the sought-after ‘entourage effect’ and utilise the natural advantages of Marlborough cultivation.

Waihopai

• Indoor cultivation
• 3-5 crops per year to be grown indoors and under glasshouse
• Can contain high levels of THC (5-30%)
  (the psychotropic ingredient in cannabis)
• Harvested and sold as premium manicured flower, milled flower and trim
• Two types available – Type 1: THC and Type 2: THC:CBD 1:1
• THC is crucial for certain medical ailments but requires secure cultivation locations

Kēkerengū

• Outdoor cultivation
• 1 crop per year to be grown outdoors
• Contains a minimal amount of THC (<1%)
• The crop has no psychotropic effect but high-CBD or CBG levels
• Harvested and sold as boutique slow-dried manicured or milled flower, machine-dried biomass - raw ingredients for extraction into oils or further purification.
• One type grown – Type 3: CBD dominant, low-THC
• CBD and other cannabinoids can be used for pharmaceutical purposes, with secondary metabolites and biomass of hemp (fibre and leaf) suitable for a variety of industries as worldwide legislation evolves.